Abstract
Crohns disease and ulcerative colitis are the two principal forms of inflammatory bowel disease (IBD). The root causes of these chronic and acute immunological disorders are unclear, but intestinal microorganisms are known to play a key role in the initiation and maintenance of disease. However, at present, there is no clear evidence for a single transmissible agent being involved in IBD aetiology. Although marked alterations occur in faecal and mucosal bacterial communities in IBD, it is unclear whether they are responsible for causing disease, or are due to changes in the gut environment that result from inflammatory reactions and extensive tissue destruction. Despite the involvement of microorganisms in inflammatory processes, antibiotic therapy has generally been unsuccessful in IBD. However, recent studies involving the use of probiotics, prebiotics and synbiotics suggest that there is potential for controlling these diseases through manipulation of the composition of the gut microbiota, and direct interactions with the gut immune system.
Keywords: Inflammatory bowel disease, ulcerative colitis, Crohn's disease, gut microbiota, probiotics, prebiotics, synbiotics, sulphur metabolism
Current Pharmaceutical Design
Title: The Gut Microbiota in Inflammatory Bowel Disease
Volume: 15 Issue: 13
Author(s): G. T. Macfarlane, K. L. Blackett, T. Nakayama, H. Steed and S. Macfarlane
Affiliation:
Keywords: Inflammatory bowel disease, ulcerative colitis, Crohn's disease, gut microbiota, probiotics, prebiotics, synbiotics, sulphur metabolism
Abstract: Crohns disease and ulcerative colitis are the two principal forms of inflammatory bowel disease (IBD). The root causes of these chronic and acute immunological disorders are unclear, but intestinal microorganisms are known to play a key role in the initiation and maintenance of disease. However, at present, there is no clear evidence for a single transmissible agent being involved in IBD aetiology. Although marked alterations occur in faecal and mucosal bacterial communities in IBD, it is unclear whether they are responsible for causing disease, or are due to changes in the gut environment that result from inflammatory reactions and extensive tissue destruction. Despite the involvement of microorganisms in inflammatory processes, antibiotic therapy has generally been unsuccessful in IBD. However, recent studies involving the use of probiotics, prebiotics and synbiotics suggest that there is potential for controlling these diseases through manipulation of the composition of the gut microbiota, and direct interactions with the gut immune system.
Export Options
About this article
Cite this article as:
Macfarlane T. G., Blackett L. K., Nakayama T., Steed H. and Macfarlane S., The Gut Microbiota in Inflammatory Bowel Disease, Current Pharmaceutical Design 2009; 15 (13) . https://dx.doi.org/10.2174/138161209788168146
DOI https://dx.doi.org/10.2174/138161209788168146 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pharmaceutical Potential of Histone Deacetylase Inhibitors
Current Pharmaceutical Design Scintigraphic Imaging of Inflammatory Processes
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Design, Synthesis and Biological Evaluation of Ferulic Acid Amides as Selective Matrix Metalloproteinase Inhibitors
Medicinal Chemistry DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Novel Therapeutic Strategies in Infection and Cancer Management
Current Aging Science Endocrine Therapy of Breast Cancer
Current Medicinal Chemistry Cellular and Physiological Effects of Short-Chain Fatty Acids
Mini-Reviews in Medicinal Chemistry IL-10 Producing Regulatory B Cells in Mice and Humans: State of the Art
Current Molecular Medicine Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Relevance of Dyslipidaemia and its Consequences in Periodontal Patients with Co-Existing Cardiovascular Disease and Diabetes Mellitus: Therapeutic Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Clostridium Difficile Infection Following Chemotherapy
Recent Patents on Anti-Infective Drug Discovery Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Computer Techniques for Drug Development from Thai Traditional Medicine
Current Pharmaceutical Design Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Cytokine and Immune System Abnormalities in Fibromyalgia and Other Central Sensitivity Syndromes
Current Rheumatology Reviews EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?
Current Drug Targets Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Current Pharmaceutical Design Lactose and Casein Cause Changes on Biomarkers of Oxidative Damage and Dysbiosis in an Experimental Model of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design